Last reviewed · How we verify
0.005% Latanoprost Ophthalmic Solution
At a glance
| Generic name | 0.005% Latanoprost Ophthalmic Solution |
|---|---|
| Also known as | Xalatan® |
| Sponsor | Santen Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- Next Generation Rocklatan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.005% Latanoprost Ophthalmic Solution CI brief — competitive landscape report
- 0.005% Latanoprost Ophthalmic Solution updates RSS · CI watch RSS
- Santen Inc. portfolio CI